Skip to main content

Table 4 Changes in NEI-VFQ-25 subscale scores from baseline to 3 months in each baseline vision group (N=98)

From: Correlation between improvement in visual acuity and QOL after Ranibizumab treatment for age-related macular degeneration patients: QUATRO study

NEI VFQ-25 Subscale Decimal visual acuity
Below 0.5 Above 0.6
CFB 95%CI P value CFB 95%CI P value
Lower Upper Lower Upper
Overall 5.1 2.7 7.5 0.00004 3.8 1.0 6.6 0.00729
General health 1.3 −3.5 6.2 0.58639 1.3 −4.4 7.0 0.65704
General vision 9.9 5.3 14.6 0.00005 9.2 3.8 14.7 0.00106
Ocular pain 1.1 −2.4 4.7 0.5226 2.9 −1.2 7.0 0.16917
Near activities 8.0 3.2 12.8 0.00123 7.8 2.3 13.3 0.00589
Distance activities 3.0 −0.9 6.8 0.12973 1.6 −2.9 6.1 0.4826
Social functioning 4.3 0.5 8.2 0.02752 3.5 −0.9 8.0 0.12142
Mental health 10.4 6.0 14.7 0.00001 4.5 −0.6 9.6 0.08608
Role difficulties 5.6 0.3 11.0 0.04003 5.4 −0.8 11.7 0.08844
Dependency 5.3 1.2 9.3 0.01196 3.8 −0.9 8.6 0.11354
Driving −2.2 −8.8 4.4 0.50748 −1.5 −8.2 5.2 0.65724
Color vision 0.8 −3.3 5.0 0.69179 −0.3 −5.1 4.5 0.9098
Peripheral vision 5.5 −0.3 11.3 0.0639 1.8 −4.9 8.4 0.5975
  1. CFB Change from baseline, CI confidence interval, NEI-VFQ-25 25-item National Eye Institute Visual Function Questionnaire
\